Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AC-262536 and ACP-105 — mechanism, side effects, legal status, and pricing.
AC-262536 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) with an azabicyclooctane naphthalene-carbonitrile structure. It acts as a partial AR agonist, showing tissue-selective anabolic effects in preclinical models. No human trials have been conducted, and it is not FDA-approved. SARMs are prohibited in athletic competition under WADA category S1.2.
ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the androgen receptor with tissue-selective anabolic effects demonstrated in preclinical models. ACP-105 is not an approved drug in any jurisdiction and has never entered human clinical trials. SARMs as a class are prohibited at all times under WADA Prohibited List S1.2 'Other Anabolic Agents'; ACP-105 falls under this class-wide ban and has been the subject of equine anti-doping metabolite-detection research.
AC-262536
ACP-105
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AC-262536
ACP-105
COA corpus from Disclosed Labs — independently tested batches only.
AC-262536
No COA data yet.
Submit testing data →ACP-105
2
COAs
99.3%
Avg purity
1
Labs
No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.
No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.
AC-262536 and ACP-105 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs